Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lupin

- PMLiVE

Pradaxa cleared for new indications in Europe

Boehringer drug set for use in deep vein thrombosis and pulmonary embolism

- PMLiVE

Boehringer aims for nintedanib approval in lung fibrosis by year end

EMA grants accelerated assessment to drug in rare disease

- PMLiVE

Boehringer sells injectables business to Hikma for $300m

Bedford Laboratories is part of troubled Ben Venue division

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Drug to reverse Pradaxa effects starts pivotal trials

Potential antidote could give Boehringer edge over rivals in oral anticoagulant competition

- PMLiVE

Novartis, Boehringer stake claims to combination COPD market

Includes combination follow-up to Spiriva

- PMLiVE

Boehringer unveils large study in stroke prevention

Will assess benefits of Pradaxa

german flag

Boehringer criticises German drug price freeze

And repeats demand for update of HTA system

- PMLiVE

Lupin names chief corporate development officer

Theresa Stevens has experience at Novartis and Aptalis

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

- PMLiVE

Boehringer lines up biosimilars of major drugs

Prospects include copies of Humira, Avastin and MabThera

- PMLiVE

Boehringer plans to open trial data back to 1998

Will partner with Sanofi, GSK, Roche, Novartis and ViiV Healthcare on online platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links